Andrew S. Davis - Apr 3, 2023 Form 4 Insider Report for Silk Road Medical Inc (SILK)

Role
Chief Commercial Officer
Signature
/s/ Mhairi Jones, by power of attorney
Stock symbol
SILK
Transactions as of
Apr 3, 2023
Transactions value $
-$233,831
Form type
4
Date filed
4/5/2023, 05:19 PM
Previous filing
Mar 6, 2023
Next filing
May 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SILK Common Stock Options Exercise $1.91K +312 +0.27% $6.11 116K Apr 3, 2023 Direct F1
transaction SILK Common Stock Options Exercise $6.98K +1.48K +1.27% $4.73 117K Apr 3, 2023 Direct F1
transaction SILK Common Stock Options Exercise $23.5K +4.97K +4.23% $4.73 122K Apr 3, 2023 Direct F1
transaction SILK Common Stock Sale -$12.3K -312 -0.25% $39.42 122K Apr 3, 2023 Direct F1, F2
transaction SILK Common Stock Sale -$58.1K -1.48K -1.21% $39.42 121K Apr 3, 2023 Direct F1, F2
transaction SILK Common Stock Sale -$196K -4.97K -4.12% $39.42 116K Apr 3, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SILK Option (right to buy) Options Exercise $0 -1.48K -3.01% $0.00 47.5K Apr 3, 2023 Common Stock 1.48K $4.73 Direct F1, F3
transaction SILK Option (right to buy) Options Exercise $0 -4.97K -18.9% $0.00 21.3K Apr 3, 2023 Common Stock 4.97K $4.73 Direct F1, F3
transaction SILK Option (right to buy) Options Exercise $0 -312 -11.79% $0.00 2.34K Apr 3, 2023 Common Stock 312 $6.11 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on May 20, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
F2 This transaction was executed in multiple trades at price ranging from $38.67 to $40.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 All of the shares subject to the option and fully vested and exercisable as of the date hereof.